Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):897-901. doi: 10.3760/cma.j.cn121090-20240704-00250.
Obinutuzumab has been widely used in patients with CD20 positve B-cell non-Hodgkin's lymphoma for more than 10 years since its launch, bringing significant clinical benefits. At present, studies at home and abroad have confirmed that the 90-minute short duration infusion of obinutuzumab is safe and feasible.In order to improve the convenience of patient infusion and the efficiency of medical institutions'infusion facilities, it is recommended for patients who do not experience grade ≥3 infusion-related adverse reactions in the first cycle of obinutuzumab infusion at the standard rate, a short duration infusion scheme should be used for subsequent treatment courses. This expert consensus is formulated to provide guidance for clinical practice.
奥妥珠单抗自上市以来已在CD20阳性B细胞非霍奇金淋巴瘤患者中广泛应用超过10年，带来了显著的临床获益。目前，国内外研究已证实奥妥珠单抗90分钟短程输注安全可行。为提高患者输注便利性及医疗机构输注设施使用效率，对于在首次以标准速率输注奥妥珠单抗时未发生≥3级输注相关不良反应的患者，建议后续疗程采用短程输注方案。制定本专家共识旨在为临床实践提供指导。
